Track market-moving stories before they get noisy

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.

While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends make up large portions of long-term returns, and in many cases, dividend contributions surpass one-third of total returns.

Headquartered in Minneapolis, U.S. Bancorp (USB - Free Report) is a Finance stock that has seen a price change of 10.36% so far this year. The company is paying out a dividend of $0.52 per share at the moment, with a dividend yield of 3.53% compared to the Banks - Major Regional industry's yield of 2.7% and the S&P 500's yield of 1.4%.

Looking at dividend growth, the company's current annualized dividend of $2.08 is up 2% from last year. Over the last 5 years, U.S. Bancorp has increased its dividend 4 times on a year-over-year basis for an average annual increase of 4.01%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. U.S. Bancorp's current payout ratio is 44%, meaning it paid out 44% of its trailing 12-month EPS as dividend.

Looking at this fiscal year, USB expects solid earnings growth. The Zacks Consensus Estimate for 2026 is $5.07 per share, which represents a year-over-year growth rate of 9.74%.

Investors like dividends for many reasons; they greatly improve stock investing profits, decrease overall portfolio risk, and carry tax advantages, among others. But, not every company offers a quarterly payout.

For instance, it's a rare occurrence when a tech start-up or big growth business offers its shareholders a dividend. It's more common to see larger companies with more established profits give out dividends. Income investors must be conscious of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, USB presents a compelling investment opportunity; it's not only an attractive dividend play, but the stock also boasts a strong Zacks Rank of #2 (Buy).

Investors looking for stocks in the Banks - Major Regional sector might want to consider either U.S. Bancorp (USB - Free Report) or Northern Trust Corporation (NTRS - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.

Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.

Both U.S. Bancorp and Northern Trust Corporation have a Zacks Rank of #2 (Buy) right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that both of these companies have improving earnings outlooks. But this is just one piece of the puzzle for value investors.

Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.

Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.

USB currently has a forward P/E ratio of 11.39, while NTRS has a forward P/E of 16.38. We also note that USB has a PEG ratio of 1.04. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. NTRS currently has a PEG ratio of 1.25.

Another notable valuation metric for USB is its P/B ratio of 1.51. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, NTRS has a P/B of 2.67.

These are just a few of the metrics contributing to USB's Value grade of B and NTRS's Value grade of D.

Both USB and NTRS are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that USB is the superior value option right now.

-

Veteran payments leader connects treasury, merchant and payments capabilities for healthcare clients

MINNEAPOLIS--(BUSINESS WIRE)--Eric Levine has joined U.S. Bank to lead the bank’s strategy to deliver more connected treasury, payments and merchant solutions to healthcare organizations.

As head of healthcare for Payments: Merchant and Institutional (PMI) Sales Distribution, Levine will advance the company’s focus on aligning cross-bank teams to deliver tailored solutions to the healthcare industry, including hospital systems, payers, medical device manufacturers and life sciences companies.

Levine will report to Peter Geronimo, executive vice president and head of PMI Sales Distribution. Geronimo joined U.S. Bank in February from Citi to build the new PMI Sales Distribution team.

“Healthcare is a priority area for U.S. Bank, with significant opportunity to help clients simplify complex payments, improve working capital and create better experiences for the people and organizations they serve,” said Geronimo. “Eric brings deep sector expertise, a strong treasury and payments background and a client-first mindset that will help us accelerate growth and deliver more value to healthcare clients.”

Levine has more than 20 years of experience in global payments, treasury solutions and the healthcare and pharmaceutical sectors. He joins U.S. Bank from Bank of America, where he helped deliver global payment solutions to large pharmaceutical and medical device companies. Previously, he served in payments leadership roles at Citi and JPMorgan. He is based in Chicago.

“Healthcare finance leaders are under increasing pressure to improve margins, strengthen cash flow visibility and simplify an increasingly complex payments landscape,” Levine said. “I’m excited to join U.S. Bank to help clients modernize their revenue cycle, streamline payments and unlock working capital. By bringing together treasury, merchant and payment capabilities, we can deliver practical, integrated solutions that improve financial performance while supporting a better experience for patients and providers alike.”

U.S. Bank continues to invest in its payments capabilities and leadership team as part of a broader Payments Transformation, one of the top three enterprise priorities at U.S. Bank. The company’s PMI organization brings together merchant acquiring, treasury management and corporate payments capabilities to help large institutional clients move money with greater speed, visibility and control.

About U.S. Bancorp

Headquartered in Minneapolis, U.S. Bancorp is the parent company of U.S. Bank National Association, the fifth-largest commercial bank in the United States. Our three major business lines serve 15 million clients globally, and our team of nearly 70,000 people invest our hearts and minds to power human potential every day. Ranked 110th on the Fortune 500, we are deeply respected for our culture and long-term stewardship and admired for our diversified business mix and product capabilities.

More News From U.S. Bancorp

Back to Newsroom

-

AI investments deliver simplified solutions and greater predictability, reliability, visibility and control

ATLANTA--(BUSINESS WIRE)--For more than three years, UPS (NYSE: UPS) has strategically deployed AI to transform global logistics. Today, the company is detailing AI-powered solutions that combine the expertise of its approximately 460,000 employees with technology to shape the future of UPS. These initiatives advance a companywide priority: simplification.

UPS is scaling AI, automation and advanced analytics to improve end-to-end visibility and the overall customer experience; make its global logistics network faster, more predictable and resilient; and ignite innovation.

Share UPS is scaling AI, automation and advanced analytics to improve end-to-end visibility and the overall customer experience; make its global logistics network faster, more predictable and resilient; and ignite innovation.

"After 118 years of reinventing logistics, we have entered a defining moment – using AI to simplify how we work across the enterprise, from customer acquisition and onboarding to how we plan, move and deliver," said Carol B. Tomé, UPS chief executive officer. "We are pairing the deep expertise of our people with the power of AI to drive faster decisions and a better experience for our customers around the globe."

Each year, UPS customers ship packages that generate billions of tracking numbers. With market volatility driving supply chain complexity, customers increasingly demand visibility that goes far beyond an anticipated delivery date. UPS is applying AI to power industry-leading end-to-end visibility and control – and to improve customer support. Specifically, the company is:

Redefining tracking to support more than 98% of customer service requests by the end of 2026, using AI and human expertise across digital and voice channels – including AI-enabled intelligent assistants in more than 20 countries. Equipping customer care teams with AI-powered, real-time shipment insights to resolve inquiries and claims faster. Transforming reverse logistics through Happy Returns, using a conversational, AI-powered experience to simplify the post-purchase journey and reduce returns fraud. Combining RFID and AI-powered tracking to deliver near real-time, package-level visibility – giving customers greater transparency, flexibility and enabling faster, smarter decisions. Further, UPS is delivering AI solutions to better serve customers around the globe including:

Scaling proprietary network planning tools that model "what if" scenarios using real-time inputs – weather, transportation delays, volume forecasts – to stress-test operations and generate execution-ready plans before disruptions impact service. Expanding a real-time digital twin of the global network to include all modes of transportation, creating a digital replica of facilities, air and ground networks, and end-to-end package flows that updates every 10 minutes – continuously tracking performance so the network can adjust and self-heal in real time. Deploying agentic "control tower" capabilities on-site with customers, combining data, predictive models and connected services to go beyond shipment tracking – flagging, prioritizing and helping resolve disruptions across complex, multi-carrier networks with full end-to-end visibility and customer control over their data. Simplifying international shipping with next-generation brokerage services that use AI, cross-border data and human expertise to help customers accurately interpret customs requirements worldwide for shipments of all sizes. Improving the cross-border experience with more predictable landed costs at checkout, more accurate product classifications via UPS Export Assure and digital trade documentation via UPS Paperless Invoice – reducing errors and accelerating processing. Enabling faster customs clearance with AI built into UPS's industry-leading brokerage capabilities. Outpacing the competition, 97% of UPS shipments clear customs on the first day of entry. "When trade rules changed, we needed to adjust fast without disrupting our customers," said Michael Garcia, vice president of operations, Audien, the world's largest over-the-counter hearing aid company. "UPS helped us take a realistic, end-to-end look at how our products move so we could stay compliant and protect service. The result was a clearer path forward during a period of uncertainty – without slowing our business."

Finally, as part of its Network of the Future transformation, UPS is redesigning operations to be more data-driven and resilient. With AI embedded across planning, routing and execution, the network will dynamically adapt to changing conditions.

"Every step we're taking supports our strategy – putting customers first, empowering our people and accelerating innovation," Tomé said. "AI isn't a buzzword at UPS. We are building on a rich history of technology embedded in every facet of our business. We are doing the work – using AI to transform global commerce."

About UPS

UPS (NYSE: UPS) is one of the world’s largest companies, with 2025 revenue of $88.7 billion, and provides a broad range of integrated logistics solutions for customers in more than 200 countries and territories. Focused on its purpose statement, “Moving our world forward by delivering what matters,” the company’s approximately 460,000 employees embrace a strategy that is simply stated and powerfully executed: Customer First. People Led. Innovation Driven. UPS is committed to reducing its impact on the environment and supporting the communities we serve around the world. More information can be found at www.ups.com, about.ups.com and investors.ups.com

More News From UPS

Back to Newsroom

United Parcel Service (UPS 1.31%) is a package delivery service. That sounds like a simple business, but it is logistically complex and requires huge capital investments. That said, moving packages around the world is vital to the global economy. UPS is an industry leader today and is likely to remain one for the next 10 years and beyond. Which is why now, while the stock is deeply unloved, could be a good time to buy stock.

UPS is going through some changes UPS' revenues have been falling, and its costs have been rising. That's a terrible trend for earnings, which have been pretty ugly. However, there's a good reason for what's happening on this industrial giant's income statement: UPS is in the middle of a major corporate overhaul. It is attempting to become a leaner and more profitable operation.

Image source: Getty Images.

Unfortunately, in the near term, that means spending more on technology and infrastructure while also shifting away from high-volume, low-margin customers. The big story on the customer front was UPS' pre-emptive move to reduce the number of packages it delivers for Amazon (AMZN +0.69%), a large but not particularly profitable customer. But there are signs that the company is making important progress, including the steady rise in revenue per piece in the U.S. market despite lower revenue in the U.S. business. This is, basically, the company's goal. The company has told investors that the second half of 2026 will be the inflection point.

There's still time to get on board To be fair, UPS' stock has already started to move higher after hitting a low in 2025. But the shares are still more then 50% below their 2022 peak, so there's still likely more recovery potential here in the near term. And, if you are looking out over a decade or longer, well, the business has a lot going for it.

Today's Change

(

-1.31

%) $

-1.41

Current Price

$

105.83

Given the massive infrastructure needed to even participate in the package delivery business, UPS has a strong industry position. Ongoing growth in e-commerce suggests that package delivery will become increasingly important over time. And once the current overhaul is complete, UPS will be a better-structured business to capitalize on that growth.

It isn't easy buying a turnaround stock, given that some turnarounds don't work out. However, UPS' turnaround appears to be taking hold. A decade from now, that will likely be glaringly obvious, which is why you should consider buying the stock now. Otherwise, you may look back and regret passing up the opportunity.

Global cold-chain network investment increases speed, visibility and end-to-end chain of custody for advanced therapies and other temperature-sensitive medicines

ATLANTA--(BUSINESS WIRE)--UPS (NYSE: UPS), the world’s No. 1 provider of complex healthcare logistics, today announced its $48 million investment in 27 temperature-controlled freight cross-dock facilities around the globe. Located in key U.S. and international markets, including Europe, Asia and the Americas, these facilities are optimized for speed and short-term storage between air and ground movements – all while maintaining specific temperature requirements. The announcement strengthens UPS’s global cold-chain network as demand grows for medicines requiring strict temperature ranges of 2 to 8 degrees Celsius, 15 to 25 degrees Celsius and frozen.

UPS is expanding the industry’s largest and most integrated cold-chain network, combining cross-dock investments, engaging in acquisitions and global infrastructure to support the rapid growth and complexity of advanced, temperature-sensitive therapies.

ShareIndustry demand for temperature-sensitive biologics is projected to expand at an 8.3% compound annual growth rate through 2033, reaching an estimated $39.1 billion, according to Growth Market Reports. Meeting this demand requires cold-chain expertise to maintain product quality and safety from manufacturing to patient.

“We have aligned our investments with our Healthcare customers’ specialized needs. Our global cross-dock facilities strengthen our end-to-end cold-chain capabilities to ensure critical treatments are delivered safely and reliably to patients around the world,” said Kate Gutmann, EVP and President of International, Healthcare and Supply Chain Solutions at UPS. “This effort – and all of our work in healthcare logistics – extends from a deep understanding that we’re doing more than moving packages. We are helping patients access the medications and treatments they need.”

Single Provider, Total Control: Integrated Freight Cross-Docks Reduce Risk

27 temperature-controlled freight cross-docks create seamless movement across transportation modes. All facilities are compliant with IATA CEIV Pharma certification, an industry-recognized standard for pharmaceutical handling and quality.A single integrated network eliminates handoffs between providers, reducing risk and increasing control.Greater accountability and real-time oversight protect high-value, temperature-sensitive therapies from excursion and disruption.24/7/365 control tower proactively monitors shipments, flags risks and enables rapid intervention to keep critical products moving.Rise of Advanced Therapies Accelerates Demand for Precision Cold-Chain Solutions

The rapidly growing biologics pipeline is increasing complexity across cold-chain logistics. According to PharmaSource, roughly one in three newly approved drugs today is a biologic more than 85% of those requiring temperature-controlled handling.

As therapies like cell and gene treatments, mRNA platforms and GLP-1 injectables come to market, healthcare supply chains are becoming more complex and risk-sensitive. Temperature excursions are a key driver of that risk, with cold-chain failures estimated to cost up to $35 billion annually and, according to WHO, contributing to up to 50% of global vaccine waste.

“Biologics and personalized treatments are driving better, more targeted care for patients,” said John Bolla, President of UPS Healthcare. “These investments reflect our commitment to continue to align our leading end-to-end supply chain to protect innovative treatments and diagnostics, supporting better patient outcomes.”

Acquisition to Advantage: Investments Are Scaling Complex Healthcare Logistics

UPS’s cross-dock expansion builds on a long-term investment in complex healthcare logistics, strengthened through acquisitions including Bomi Group, Frigo Trans and BPL in Europe and Andlauer Healthcare Group in North America. More recently, UPS expanded its Incheon, Korea air hub to support fast-growing pharmaceutical trade flows, as South Korea imported nearly $9.7 billion in pharmaceutical products in 2025, according to Observatory of Economic Complexity data.

The result is a more responsive supply chain that keeps high-value, time- and temperature-sensitive healthcare shipments moving seamlessly across air, ocean, ground and final mile. As demand grows, UPS’s integrated network is built to manage this complexity today and scale for what’s ahead.

About UPS

UPS (NYSE: UPS) is one of the world’s largest companies, with 2025 revenue of $88.7 billion, and provides a broad range of integrated logistics solutions for customers in more than 200 countries and territories. Focused on its purpose statement, “Moving our world forward by delivering what matters,” the company’s approximately 460,000 employees embrace a strategy that is simply stated and powerfully executed: Customer First. People Led. Innovation Driven. More information can be found at www.ups.com, about.ups.com and investors.ups.com.

About UPS Healthcare

UPS Healthcare delivers unparalleled healthcare logistics expertise to its customers around the world. UPS Healthcare has 19.2+ million square feet of cGMP and GDP-compliant healthcare distribution space globally. Services include inventory management, cold chain packaging and shipping, storage and fulfillment of medical devices, and lab and clinical trial logistics. UPS Healthcare's global infrastructure, its UPS® Premier visibility service, its track and trace technology, and its global quality system are well-suited to meet today's complex logistics demands for the pharmaceutical, medical device, and laboratory diagnostic industries. Visit Healthcare.ups.com for more information.

Sources: Growth Market Reports; PharmaSource; Westwell Lab; World Health Organization; Observatory of Economic Complexity.

UPS (NYSE: UPS), the world’s No. 1 provider of complex healthcare logistics, today announced its $48 million investment in 27 temperature-controlled freight cross-dock facilities around the globe. Located in key U.S. and international markets, including Europe, Asia and the Americas, these facilities are optimized for speed and short-term storage between air and ground movements – all while maintaining specific temperature requirements. The announcement strengthens UPS’s global cold-chain network as demand grows for medicines requiring strict temperature ranges of 2 to 8 degrees Celsius, 15 to 25 degrees Celsius and frozen.

Industry demand for temperature-sensitive biologics is projected to expand at an 8.3% compound annual growth rate through 2033, reaching an estimated $39.1 billion, according to Growth Market Reports. Meeting this demand requires cold-chain expertise to maintain product quality and safety from manufacturing to patient.

“We have aligned our investments with our Healthcare customers’ specialized needs. Our global cross-dock facilities strengthen our end-to-end cold-chain capabilities to ensure critical treatments are delivered safely and reliably to patients around the world,” said Kate Gutmann, EVP and President of International, Healthcare and Supply Chain Solutions at UPS. “This effort – and all of our work in healthcare logistics – extends from a deep understanding that we’re doing more than moving packages. We are helping patients access the medications and treatments they need.”

Single Provider, Total Control: Integrated Freight Cross-Docks Reduce Risk

27 temperature-controlled freight cross-docks create seamless movement across transportation modes. All facilities are compliant with IATA CEIV Pharma certification, an industry-recognized standard for pharmaceutical handling and quality.A single integrated network eliminates handoffs between providers, reducing risk and increasing control.Greater accountability and real-time oversight protect high-value, temperature-sensitive therapies from excursion and disruption.24/7/365 control tower proactively monitors shipments, flags risks and enables rapid intervention to keep critical products moving.Rise of Advanced Therapies Accelerates Demand for Precision Cold-Chain Solutions

The rapidly growing biologics pipeline is increasing complexity across cold-chain logistics. According to PharmaSource, roughly one in three newly approved drugs today is a biologic more than 85% of those requiring temperature-controlled handling.

As therapies like cell and gene treatments, mRNA platforms and GLP-1 injectables come to market, healthcare supply chains are becoming more complex and risk-sensitive. Temperature excursions are a key driver of that risk, with cold-chain failures estimated to cost up to $35 billion annually and, according to WHO, contributing to up to 50% of global vaccine waste.

“Biologics and personalized treatments are driving better, more targeted care for patients,” said John Bolla, President of UPS Healthcare. “These investments reflect our commitment to continue to align our leading end-to-end supply chain to protect innovative treatments and diagnostics, supporting better patient outcomes.”

Acquisition to Advantage: Investments Are Scaling Complex Healthcare Logistics

UPS’s cross-dock expansion builds on a long-term investment in complex healthcare logistics, strengthened through acquisitions including Bomi Group, Frigo Trans and BPL in Europe and Andlauer Healthcare Group in North America. More recently, UPS expanded its Incheon, Korea air hub to support fast-growing pharmaceutical trade flows, as South Korea imported nearly $9.7 billion in pharmaceutical products in 2025, according to Observatory of Economic Complexity data.

The result is a more responsive supply chain that keeps high-value, time- and temperature-sensitive healthcare shipments moving seamlessly across air, ocean, ground and final mile. As demand grows, UPS’s integrated network is built to manage this complexity today and scale for what’s ahead.

About UPS

UPS (NYSE: UPS) is one of the world’s largest companies, with 2025 revenue of $88.7 billion, and provides a broad range of integrated logistics solutions for customers in more than 200 countries and territories. Focused on its purpose statement, “Moving our world forward by delivering what matters,” the company’s approximately 460,000 employees embrace a strategy that is simply stated and powerfully executed: Customer First. People Led. Innovation Driven. More information can be found at www.ups.com, about.ups.com and investors.ups.com.

About UPS Healthcare

UPS Healthcare delivers unparalleled healthcare logistics expertise to its customers around the world. UPS Healthcare has 19.2+ million square feet of cGMP and GDP-compliant healthcare distribution space globally. Services include inventory management, cold chain packaging and shipping, storage and fulfillment of medical devices, and lab and clinical trial logistics. UPS Healthcare's global infrastructure, its UPS® Premier visibility service, its track and trace technology, and its global quality system are well-suited to meet today's complex logistics demands for the pharmaceutical, medical device, and laboratory diagnostic industries. Visit Healthcare.ups.com for more information.

Sources: Growth Market Reports; PharmaSource; Westwell Lab; World Health Organization; Observatory of Economic Complexity.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260622325874/en/

United Parcel Service (UPS - Free Report) closed the most recent trading day at $107.24, moving +2.27% from the previous trading session. The stock outperformed the S&P 500, which registered a daily loss of 0.37%. Meanwhile, the Dow gained 0.29%, and the Nasdaq, a tech-heavy index, lost 1.33%.

The stock of package delivery service has risen by 3.8% in the past month, lagging the Transportation sector's gain of 4.68% and overreaching the S&P 500's gain of 2.02%.

Market participants will be closely following the financial results of United Parcel Service in its upcoming release. The company is predicted to post an EPS of $1.67, indicating a 7.74% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $21.51 billion, reflecting a 1.34% rise from the equivalent quarter last year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $7.1 per share and a revenue of $89.78 billion, signifying shifts of -0.84% and +1.26%, respectively, from the last year.

Investors should also pay attention to any latest changes in analyst estimates for United Parcel Service. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. United Parcel Service is holding a Zacks Rank of #3 (Hold) right now.

Looking at valuation, United Parcel Service is presently trading at a Forward P/E ratio of 14.77. For comparison, its industry has an average Forward P/E of 15.11, which means United Parcel Service is trading at a discount to the group.

We can additionally observe that UPS currently boasts a PEG ratio of 1.67. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Transportation - Air Freight and Cargo stocks are, on average, holding a PEG ratio of 1.62 based on yesterday's closing prices.

The Transportation - Air Freight and Cargo industry is part of the Transportation sector. Currently, this industry holds a Zacks Industry Rank of 105, positioning it in the top 44% of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.

Investors might want to bet on Globe Life (GL - Free Report) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.

The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.

As such, the Zacks rating upgrade for Globe Life is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.

For Globe Life, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.

Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for Globe LifeThis life and health insurance company is expected to earn $15.64 per share for the fiscal year ending December 2026, which represents no year-over-year change.

Analysts have been steadily raising their estimates for Globe Life. Over the past three months, the Zacks Consensus Estimate for the company has increased 2.3%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of Globe Life to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

The Fidelity MSCI Consumer Staples Index ETF (FSTA +1.73%) offers broader diversification through its 96 holdings, while the State Street Consumer Staples Select Sector SPDR ETF (XLP +1.87%) provides a more concentrated portfolio with higher historical dividend yields.

Investors often turn to the consumer staples sector for stability and defensive positioning by holding companies that produce essential goods like food and hygiene products. While FSTA and XLP both target this space with identical, ultra-low costs, they differ significantly in portfolio concentration, liquidity, and historical yield payouts.

Snapshot (cost & size)MetricFSTAXLPIssuerFidelitySPDRExpense ratio0.08%0.08%1-yr return (as of June 16, 2026)5.4%5.4%Dividend yield2.2%2.6%Beta0.550.54AUM$1.4 billion$14.6 billionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

Both funds are highly cost-efficient, each charging just 0.08% annually. However, XLP has historically provided a higher payout to investors, with its trailing-12-month dividend yield sitting 40 basis points above the yield offered by Fidelity’s fund.

Performance & risk comparisonMetricFSTAXLPMax drawdown (5 yr)(16.6%)(16.3%)Growth of $1,000 over 5 years (total return)$1,408$1,380What's insideThe SPDR ETF focuses on large-cap stability by tracking consumer staples companies within the S&P 500. Its portfolio is relatively concentrated, with just 36 holdings, and its sector allocation consists of consumer defensive at 99% and consumer cyclical at 1%. Its largest positions include Walmart (WMT +2.11%) at 11.03%, Costco Wholesale (COST +0.80%) at 9.05%, and Procter & Gamble (PG +2.15%) at 7.2%. The fund was launched in 1998 and has a trailing-12-month dividend payout of $2.18 per share.

In contrast, the Fidelity ETF provides broader market reach by tracking the MSCI USA IMI Consumer Staples 25/50 Index with 96 holdings. It allocates 98% to consumer defensive and 2% to consumer cyclical stocks. Its top holdings are also Walmart, Costco, and P&G at 14.62%, 11.69%, and 8.69%, respectively. Fidelity’s fund, which was launched in 2013, paid $1.16 per share in dividends over the trailing 12 months. FSTA’s broader approach results in slightly more exposure to mid-cap companies compared to the SPDR fund.

For more guidance on ETF investing, check out the full guide at this link.

What this means for investorsOn a surface level, these two ETFs look pretty alike: same expense ratios, same one-year returns. Their identical top 10 holdings account for roughly the same proportion of their portfolios (between 62% and 65%).

Where the SPDR and Fidelity ETFs do differ, it's pretty stark. FSTA holds well over twice as many stocks, for one thing. And despite the diversification benefits one might assume would accompany that, the fact is the top three holdings account for about 36% of the portfolio. (The top three holdings only make up 27% of XLP's portfolio.) Investors' comfort level with that concentration risk may vary; Walmart and Costco delivered strong returns over the past half-decade, but P&G has trailed the market by more than 60 percentage points over the past five years. That said, it's not a foregone conclusion Walmart and Costco will continue to deliver strong returns. Both stocks have P/E ratios above 40, somewhat steep for a retail name. Investors are clearly already pricing in robust growth for both stocks.

One final key difference is their assets under management. XLP has more than $14 billion in AUM, while FSTA has about 1/10th as much. Accordingly, their average trading volume has a similar differential. Given my druthers, I'd be more inclined to buy shares of the SPDR ETF because it's less concentrated in the top names and offers more liquidity. XLP’s slightly higher dividend yield is just the cherry on top.

Costco Wholesale (NASDAQ: COST | COST Price Prediction) trades near $985, a price that demands flawless execution into a tightening macro even as the best-in-class compounder narrative remains intact. Kevin Warsh’s first meeting as Fed Chair lands with sticky inflation keeping long yields elevated, and high-multiple stocks have already started bleeding multiple compression into premium consumer staples.

Costco runs a membership-warehouse model that turns fee income into low prices, with Kirkland Signature and Costco Logistics extending the moat. The flywheel produced $275.24B in FY25 revenue and $18.21 in EPS, with $13.34B in operating cash flow.

After climbing 14.74% YTD to $986.68, COST has given back 5.94% over the past month as the market reprices the multiple a slow-and-steady retailer deserves when 10-year yields refuse to budge.

The Flywheel Keeps Spinning Faster Than the Share Price Q3 FY26 delivered EPS of $4.93 on revenue of $70.53B, an 11.6% YoY jump beating consensus, with digitally-enabled comparable sales up 21.5% and e-commerce traffic up 37%. Membership fee income grew 10.7% to $1.37B, the worldwide renewal rate held at 89.7%, and executive members now drive 75.0% of net sales. Net income jumped 15.2%.

Management plans to reach roughly 940 warehouses by FY26 year-end. Quarterly earnings growth running at 45.5% YoY makes a forward P/E of 44 look less absurd in context. Analyst sentiment broadly agrees, with 22 of 37 analysts rating it Buy or Strong Buy.

A 49 P/E Meets a Fed That Cannot Cut Fast Enough Costco trades at a trailing P/E of 49, a forward P/E of 44, and 13 times book, with a PEG of 4.8. For a 3% net margin retailer, that pricing assumes years of uninterrupted execution. Vanguard’s 2026 outlook warns core inflation likely stays above 2.5%, leaving the Fed limited scope to cut below a 3.5% neutral rate. Sticky inflation plus elevated long yields compresses premium multiples.

COST trades below its 50-day moving average of $1,004.25 and only modestly above the 200-day at $957.56, with a 52-week high of $1,096.50 already in the rearview.

Great Business, Demanding Entry Price Nothing in the fundamentals justifies selling a compounder with 82.1M paid memberships and double-digit fee growth. The multiple does not justify chasing the stock into Warsh’s first meeting. A pullback into the low-$900s, or a broader market reset toward $830, would offer real margin of safety. Watch comp sales, membership growth (now running near 4.1%), and any dovish signal from the Fed.

Where the Numbers Leave Costco Today Costco currently trades at $986.68, up 14.74% YTD versus a 10.03% gain for the S&P 500, but down 5.94% over the past month. The consensus analyst target of $1,082.33 implies roughly 10% upside. Across 37 covering analysts:

Strong Buy: 3 Buy: 19 Hold: 13 Sell: 1 Strong Sell: 1 Valuation runs hot with EV/EBITDA at 29 and a 0.55% dividend yield, against a market cap of $434.4B.

At $985, Patience Has a Price Tag At $985, Costco sits in a tension zone. The business fires on every cylinder that matters, yet the entry price assumes the macro cooperates and the multiple holds, both of which look uncertain with Warsh inheriting a sticky inflation problem and the market already punishing high multiples.

The bull case strengthens if Costco pulls back toward $830 on broader multiple compression, or if comps reaccelerate above 10% adjusted while the Fed signals real cuts. The bear case requires a real crack in the 89.7% renewal rate or membership growth, which Q3 did not show. Until one of those breaks, the setup remains in stalemate.

The cost of patience is missing the drift to consensus. The cost of acting is paying 44 times forward earnings for a 3% margin retailer into a tightening cycle. That asymmetry explains why many investors are sitting on their hands at this price.

When most people think of trillion-dollar stocks, they think of Nvidia and Apple. But there's a quieter class of financial titans: companies that have built their size not on chip architecture or software ecosystems, but on the way ordinary people live, shop, eat, and spend.

These three companies are simple and foundational, and right now, each one is doing something worth watching.

Image source: Getty Images.

1. Walmart Walmart (WMT +2.11%) became the first traditional retailer to cross a $1 trillion market valuation in February 2026, and the milestone wasn't accidental. The company's path to the trillion-dollar club ran through technology, not store counts. Its e-commerce business now represents 18% of total revenue and grew 24% to $150 billion in fiscal 2026. Same-day delivery now reaches 95% of U.S. households, a logistics feat that most companies couldn't execute in a decade, let alone a few years.

What's less covered is what this means for everyday shoppers. Walmart's AI shopping agent, Sparky, drives baskets that are 35% larger than standard shopping sessions. The company's Wally AI tool for internal merchants helps identify out-of-stock issues in real time. These tools aren't just about cutting costs -- they're about making sure the person shopping on a phone at 11 p.m. can find what they need and get it the next morning.

Today's Change

(

2.11

%) $

2.47

Current Price

$

119.65

2. Costco Costco (COST +0.80%) is doing something unusual in the current economic climate: Its members are spending more per visit, not less. Average transaction size rose 7.3% worldwide during its third quarter because members trust the warehouse chain to deliver value when budgets are stretched.

Membership fee income grew 13.6% in the most recent quarter, and the company now counts 82.1 million paid household members globally. The model is almost counterintuitive: Costco charges people for the privilege of shopping there, and those people reward the company with loyalty that very few consumer brands achieve. Executive memberships -- the higher membership tier -- account for 75.8% of worldwide sales.

For consumers, the appeal is increasingly practical. Costco's fuel prices have been a meaningful draw during a period when gasoline costs have risen sharply, and the company has passed tariff savings directly to shoppers on categories like cookware and bedding. That's a version of brand trust that pays dividends for decades.

Today's Change

(

0.80

%) $

7.59

Current Price

$

958.95

4. Berkshire Hathaway Berkshire Hathaway (BRKA +0.74%) (BRKB +0.86%), under new CEO Greg Abel, is not the company it was a year ago. This isn't really a criticism. It's an observation worth sitting with.

Abel's first major independent deal was the acquisition of homebuilder Taylor Morrison and its merger with Clayton Homes, creating one of the U.S.'s largest homebuilding platforms. The consumer logic is direct: There is a deficit of approximately 7 million homes in the U.S., and Berkshire is now positioned to help fill it. At the same time, Berkshire made a $10 billion investment in Alphabet, bringing the Google parent into the top four Berkshire holdings alongside Coca-Cola, Apple, and American Express. 

Today's Change

(

0.86

%) $

4.22

Current Price

$

492.91

To me, Berkshire remains the most underappreciated consumer story in the market -- not because it's cheap, but because its portfolio of consumer franchises is more durable than almost anything else a retail investor can own.

American Express is an advertising partner of Motley Fool Money. Micah Zimmerman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, American Express, Apple, Berkshire Hathaway, Costco Wholesale, Nvidia, and Walmart. The Motley Fool has a disclosure policy.

© 2021 Getty Images / Getty Images News via Getty Images

Costco (NASDAQ:COST | COST Price Prediction) just posted its strongest comp sales quarter of the fiscal year and the market shrugged. Q3 FY26 comps came in at 9.8%, membership fees grew 10.7%, and digitally-enabled sales jumped 21.5%.

Yet shares have slipped 5.94% over the past month. That gap between operational momentum and price action is the kind of setup I pay attention to. Costco trades at $986.68. Can it reach $1,250 in 2027? Here is the path.

What’s Holding Costco Back Right Now The simple answer: valuation. Costco trades at roughly 49 times trailing earnings, and that multiple gets harder to defend when consumer confidence is cracking. University of Michigan sentiment dropped to 49.8 in April 2026, the lowest reading in the past year and approaching recessionary territory. Even a 0.87 beta does not protect a stock priced for perfection when the macro narrative turns.

Shares reflect that. Shares peaked near $1,048.95 on May 15 before pulling back. YTD is still respectable at +14.74%, but the 1-year return is just 0.8%. An EVP also sold 700 shares at $993 on April 1. These are simply reasons shares are stuck.

Wall Street Sees 9.7% Upside. Our Model Says 8.5% Consensus is constructive but cautious. The analyst target sits at $1,082.33, with 3 strong buys, 19 buys, 13 holds, 1 sell, and 1 strong sell. Bullish skew runs 59%. Citi resumed coverage of Costco with a Neutral rating and $1,020 price target.

Our base case lands at $1,070.32 with 90% confidence, with an optimistic case of $1,151.08 and a bear case of $976.48. My read: both Wall Street and our model are underweighting earnings acceleration. YoY earnings growth of 45.5% reads as a growth-stock figure attached to a recession-resistant business. That combination usually gets re-rated higher, not lower.

The Path to $1,250 Per Share Reaching $1,250 from today’s price of $986.68 would require a gain of 26.7%.

With forward EPS of $21.69, a price of $1,250 implies a forward P/E of 58x. Our base case of $1,070.32 already implies 50x, meaning the bold target requires roughly 8x of additional multiple expansion.

Is that crazy? Not given the inputs. The 247Factor adjustment of 1.075 is driven by strong earnings momentum and 59% bullish analyst sentiment.

The catalysts are real: digitally enabled comparable sales rose 21.1% in the four weeks ending May 31 while total comps grew 12.5%. Costco is also positioned to outperform Walmart as gas prices surge because its affluent membership base absorbs fuel inflation.

And CFO Gary Millerchip announced targeted Kirkland Signature price reductions in May, a margin-positive trade in disguise. The primary risk is a consumer sentiment collapse that derails membership renewals.

Where Costco Trades Today vs Its Earnings Power At $986.68 on forward EPS of $21.69, the stock trades around 45x forward earnings. Expensive on paper. Reasonable when you consider 89.7% worldwide renewal rates and 75% executive membership penetration.

Shares sit between a 52-week low of $841.69 and high of $1,096.50. Zoom out and the long term is striking: COST is up 649.43% over the last 10 years. That is the multiple-expansion engine in action.

Is $1,250 Realistic? Here’s My Take Reaching $1,250 requires a 26.7% gain and a re-rating to roughly 58x forward earnings. That is a stretch, but it is the kind of stretch this business has earned before.

Three things need to go right: earnings growth stays north of 13% per quarter, membership economics keep compounding, and the macro avoids an outright recession. What derails it is a sharp drop in renewal rates or a sentiment-driven multiple compression. Returns at this level shouldn’t be expected every year, but we’ve outlined the blueprint for how Costco could reach $1,250 in 2027.

Key Takeaways Costco's membership model is strengthening through deeper engagement, not just member additions.Executive members rose 9.6% year over year to 41.2 million and accounted for 75% of sales.Membership fee income climbed 10.7% to $1.37B, with renewals strong in the U.S., Canada and globally. Costco Wholesale Corporation’s (COST - Free Report) membership model appears to be gaining strength not simply through member additions, but through deeper engagement. The latest quarter saw high renewal rates, rising executive membership penetration and solid membership income growth, suggesting member loyalty remains intact.

Membership fee income increased 10.7% year over year to $1,373 million during the third quarter of fiscal 2026. While part of the gain reflected the membership fee increase implemented in September 2024, management noted that membership income still grew 7%, excluding the fee increase and foreign exchange impacts, driven by member growth and executive membership upgrades.

The most notable development was the continued expansion of executive memberships. Executive members reached 41.2 million at quarter-end, up 9.6% from the prior year, far outpacing overall paid membership growth of 4.1%. The company also launched its executive membership program in China and reported stronger-than-expected early adoption. Executive members accounted for 75% of sales, underscoring their importance to the overall membership ecosystem.

Management emphasized that executive members typically shop more often and spend more than standard members, making this mix shift particularly meaningful for the overall membership ecosystem.

Renewal metrics also remained exceptionally strong. Costco reported a 92.2% renewal rate in the United States and Canada and an 89.7% renewal rate worldwide. Management highlighted that targeted digital communication and retention initiatives helped offset pressure from the growing mix of online sign-ups, which historically renew at lower rates.

Taken together, rising executive penetration, resilient renewals and sustained membership income growth indicate that Costco is not only retaining members effectively but also increasing the value it derives from each membership relationship.

Walmart & BJ’s Wholesale: Membership Momentum Remains StrongCostco is not the only retailer benefiting from a stronger membership ecosystem. Walmart Inc. (WMT - Free Report) continues to deepen engagement through Walmart+, with membership fee revenues rising 17.4% globally in the first quarter and Walmart+ recording a record level of net additions. Management noted that membership has become an increasingly important profit stream, with members spending significantly more than non-members and utilizing benefits such as fuel savings and faster delivery.

BJ's Wholesale Club Holdings, Inc. (BJ - Free Report) reported robust membership trends. Membership fee income increased 9.9% year over year to a record $132.4 million, supported by strong member acquisition, retention and higher-tier membership penetration. Management emphasized that higher-tier members remain more engaged, shop more frequently and generate greater lifetime value.

Like Costco, both Walmart and BJ’s Wholesale are demonstrating that a growing base of loyal, higher-value members can drive recurring revenues, stronger engagement and long-term sales growth.

What the Latest Metrics Say About CostcoCostco has seen its shares tumble 1.4% over the past three months against the industry’s growth of 2.2%. 
 

Image Source: Zacks Investment Research

From a valuation standpoint, Costco's forward 12-month price-to-earnings ratio stands at 43.14, higher than the industry’s ratio of 31.26. However, it is trading below its 12-month median level of 46.55, indicating some moderation in valuation despite sustained investor confidence in the stock.
 

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Costco’s current financial-year sales and earnings per share implies year-over-year growth of 9.4% and 13.3%, respectively. For the next fiscal year, the consensus estimate indicates a 7.8% rise in sales and 10.2% growth in earnings.

The consensus estimate for earnings per share for the current and next fiscal year has increased by 5 cents and 6 cents to $20.38 and $22.46, respectively, over the past 30 days.

Image Source: Zacks Investment Research

Costco currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways BJ's membership fee income rose 9.9% to $132.4M as total members reached an all-time high.Higher-tier members are more engaged, with BJ's holding a 90% tenured renewal rate and 42% penetration.BJ's Texas clubs ran 33% ahead of plan, adding about 100,000 members in Dallas-Fort Worth. BJ's Wholesale Club Holdings, Inc. (BJ - Free Report) is solidifying its position as a compelling retail stock to watch, supported by record-breaking membership metrics. The company generated $132.4 million in membership fee income in the first quarter of fiscal 2026, up 9.9% from the prior year, as total members reached an all-time high. Management attributed the gain to acquisition, retention and higher-tier membership penetration across both new and existing clubs.

The membership base is expanding and becoming more valuable. Management said higher-tier members are more engaged, shop more often and deliver greater lifetime value. The company maintained a 90% tenured membership renewal rate and reported more than 8 million members, with 42% higher-tier penetration.

This strong membership foundation also underpins steady customer traffic and ongoing market share gains. This was evident as BJ’s expanded operations in Texas, its 22nd state. In May 2026, BJ indicated that membership acquisition across the four new Texas clubs was running an impressive 33% ahead of plan, amassing approximately 100,000 members in the Dallas-Fort Worth region alone.

BJ's noted that membership fee income has grown every year for more than 25 years. The metric has expanded at an 8% CAGR from fiscal 1997 through fiscal 2025. That kind of consistency gives the latest quarter more weight, especially in a retail environment where consumer spending remains uneven. Management did caution that membership fee income growth should moderate as the company laps last year's fee increase. However, the underlying health of this engine remains exceptionally strong.

The committed shoppers provide BJ’s with a recurring membership-fee stream. The reliable, high-margin revenues generated by these loyal members give the warehouse club operator a distinct competitive advantage and substantial financial durability during dynamic economic periods.

Walmart & Costco: Membership Momentum Remains StrongWalmart Inc. (WMT - Free Report) continues to deepen engagement through Walmart+, with membership fee revenues rising 17.4% globally in the first quarter of fiscal 2027 and Walmart+ recording a record level of net additions. Management noted that membership has become an increasingly important profit stream, with members spending significantly more than non-members and utilizing benefits such as fuel savings and faster delivery.

Costco Wholesale Corporation’s (COST - Free Report) membership model appears to be gaining strength not simply through member additions, but through deeper engagement. Costco’s membership fee income increased 10.7% year over year to $1,373 million during the third quarter of fiscal 2026. Executive members reached 41.2 million at quarter-end, up 9.6% from the prior year, far outpacing overall paid membership growth of 4.1%. With executive members representing 75% of sales and early adoption strong in China, Costco continues to benefit from loyalty and higher-tier penetration.

What the Latest Metrics Say About BJ's WholesaleBJ's Wholesale has seen its shares tumble 26.5% over the past year compared with the industry’s decline of 10.6%. 
 

Image Source: Zacks Investment Research

From a valuation standpoint, BJ's forward 12-month price-to-earnings ratio stands at 17.99, lower than the industry’s ratio of 18.13 and the median level of 20.57. BJ carries a Value Score of B. 
 

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for BJ’s current financial-year sales and earnings per share implies year-over-year growth of 9.3% and 2.5%, respectively. For the next fiscal year, the consensus estimate indicates a 7.1% rise in sales and 8.5% growth in earnings.
 

Image Source: Zacks Investment Research

BJ currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

-

Launching today on Microsoft 365 Copilot Cowork, with availability expanding across compatible AI platforms

NEW YORK--(BUSINESS WIRE)--Moody’s Corporation (NYSE: MCO) today announced the release of its first set of AI skills – purpose-built, platform-agnostic instruction kits that encode Moody’s analytical frameworks and connect AI agents to its decision-grade intelligence. Available across compatible AI platforms beginning with Microsoft 365 Copilot Cowork, Moody’s skills enable customers to execute complex analytical workflows through a single natural-language request, with outputs grounded in Moody’s proprietary ratings, research, and risk intelligence.

“Moody’s is among the first financial data providers to deliver a full library of skills on an open standard, and today’s launch is just the beginning,” said Cristina Pieretti, Head of Digital Content and Innovation at Moody’s. “AI platforms are becoming the interface for financial decision-making, and the next phase of adoption will be defined by execution. Skills are how we encode Moody’s expertise into that execution layer.”

Skills are emerging as the standard for how AI agents execute specialist work. By publishing its analytical frameworks as skills that run on the platforms where market participants already build and operate, Moody’s is embedding its decision-grade intelligence at the center of how financial analysis is executed across the industry.

Moody’s first wave of skills covers high-priority financial workflows where Moody’s expertise is most concentrated:

Earnings Call Summary – Summarizes earnings call transcripts, covering revenue trends, pricing dynamics, consumer health, tariff exposure, and more. Peer Analysis – Produces an investor-grade comparison across leverage, profitability, ESG, credit quality, and more. Public Information Book – Builds a comprehensive dossier on a single entity, spanning financials, governance, competitive landscape, and risk profile. Rating Pitch – Generates a structured pitch deck covering sector context, rating history, and peer positioning. Sector Analysis – Combines Moody’s proprietary research with live market intelligence to deliver a full sector-level outlook. Each skill encodes analytical steps and quality standards to produce outputs that are consistent, sourced, and defensible for high-stakes decision-making in regulated environments. A skill defines how the work is done; Moody's Model Context Protocol (MCP) servers connect it to the data it runs on. MCP is the open standard that lets an AI agent draw directly on Moody's ratings, research, and risk intelligence, so the outputs are grounded in proprietary data rather than general-purpose web content.

A skill teaches an AI agent how to perform a task to a defined standard, captured in a simple, shareable instruction file. Moody's skills are built on the open SKILL.md format, which originated with Anthropic and has since been adopted by platforms like OpenAI, Microsoft, Google, and Amazon. Because the standard is open, the institutional knowledge encoded in each skill is a durable, portable asset rather than a capability locked to one provider, built once and able to run on any compatible platform.

Moody's plans to expand its library of skills to include credit analysis, lead generation, third-party due diligence, and insurance underwriting – extending its analytical frameworks into more of the high-stakes workflows where financial professionals operate. Each new skill will follow the same open, platform-agnostic standard, ensuring the institutional knowledge remains a durable, portable asset across compatible AI platforms.

To learn more, visit https://www.moodys.com/web/en/us/creditview/blog/moodys-skills.html

About Moody’s Corporation

In a world shaped by increasingly interconnected risks, Moody's (NYSE: MCO) data, insights, and innovative technologies help customers develop a holistic view of their world and unlock opportunities. With a rich history of experience in global markets and a diverse workforce of approximately 16,000 across more than 40 countries, Moody's gives customers the comprehensive perspective needed to act with confidence and thrive. Learn more at moodys.com.

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this document are forward-looking statements and are based on future expectations, plans and prospects for Moody’s business and operations that involve a number of risks and uncertainties. Such statements involve estimates, projections, goals, forecasts, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements. Stockholders and investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements and other information in this document are made as of the date hereof, and Moody’s undertakes no obligation (nor does it intend) to publicly supplement, update or revise such statements on a going-forward basis, whether as a result of subsequent developments, changed expectations or otherwise, except as required by applicable law or regulation. Factors, risks and uncertainties as well as other risks and uncertainties that could cause Moody’s actual results to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements are described in greater detail under “Risk Factors” in Part I, Item 1A of Moody’s annual report on Form 10-K for the year ended December 31, 2025, and in other filings made by the Company from time to time with the SEC or in materials incorporated herein or therein. Stockholders and investors are cautioned that the occurrence of any of these factors, risks and uncertainties may cause the Company’s actual results to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements, which could have a material and adverse effect on the Company’s business, results of operations and financial condition.

More News From Moody's Corporation

Back to Newsroom

, /PRNewswire/ -- M&T Bank Corporation ("M&T") (NYSE:MTB) will announce its second quarter 2026 earnings results in a press release that will be issued before the market opens on Wednesday, July 15, 2026.

Following the release, M&T will conduct a conference call and webcast at 8:00 a.m. (ET) to discuss the earnings results. The conference call and webcast may contain forward-looking statements and other material information.

Domestic callers wishing to participate in the call may dial toll free (800) 347-7315. International participants, using any applicable international calling codes, may dial (785) 424-1755. Callers should reference M&T Bank Corporation or the conference ID #MTBQ226. The conference call will be webcast live through M&T's website at https://ir.mtb.com/news-events/events-presentations.

A replay of the call will be available through Wednesday, July 22, 2026, by calling (800) 695-2533 or (402) 530-9029 for international participants. No conference ID or passcode is required. The webcast archive of the conference call will be available by 3:00 p.m., July 15, 2026, on M&T's website at https://ir.mtb.com/news-events/events-presentations.

About M&T
M&T Bank Corporation is a financial holding company headquartered in Buffalo, New York. M&T's principal banking subsidiary, M&T Bank, provides banking products and services with a branch and ATM network spanning the eastern U.S. from Maine to Virginia and Washington, D.C. Trust-related services are provided in select markets in the U.S. and abroad by M&T's Wilmington Trust-affiliated companies and by M&T Bank. For more information on M&T Bank, visit www.mtb.com.

Equal Housing Lender. ©2026 M&T Bank. NMLS #381076. Member FDIC. All Rights Reserved.

Investor Contact:
Rajiv Ranjan
Steve Wendelboe
(716) 842-5138

Media Contact:
Frank Lentini
(929) 651-0447

SOURCE M&T Bank Corporation

Chief Customer and Transformation Officer to oversee growth and community engagement across Delaware

, /PRNewswire/ -- M&T Bank (NYSE: MTB) today announced the appointment of Krista Phillips as its Delaware regional president, effective July 1, 2026. Phillips, who also serves as chief customer and transformation officer, will lead the bank's local growth and community engagement efforts across Delaware while continuing in her current enterprise role. 

Krista Phillips, Chief Customer and Transformation Officer, Delaware Regional President, M&T Bank Phillips has more than 25 years of experience in the financial services industry and deep expertise in customer strategy, marketing and product development. She joined M&T Bank in 2025 as its first chief customer officer, where she leads the bank's customer experience, marketing and analytics teams. Prior to M&T, she held senior leadership roles at Wells Fargo and Citi, focused on consumer banking, brand management and customer engagement.

"Krista Phillips' deep banking expertise, strong leadership and commitment to our customers and communities make her the right choice to lead our efforts in Delaware," said Augie Chiasera, head of community markets at M&T Bank. "She understands how to bring together the full capabilities of M&T in service of our clients, and she has a clear track record of delivering results while strengthening the communities we serve." 

"I'm honored to take on the role of Delaware regional president and build on M&T's longstanding commitment to this community," said Krista Phillips, chief customer and transformation officer and Delaware regional president at M&T Bank. "Delaware is home to incredible businesses, organizations and families, and I look forward to working alongside our teams to help our customers achieve their goals and strengthen the communities where we live and work."

Under its local engagement model, M&T organizes its footprint into community regions led by regional presidents who oversee integrated teams across retail banking, business banking, commercial banking, wealth management and community development. These teams tailor strategies to local needs, combining the capabilities of a large institution with the responsiveness of a community bank. 

M&T serves Delaware customers and business clients through 55 branches across the state and employs more than 1,600 colleagues locally. In Delaware, M&T and its employees contribute thousands of volunteer hours each to local causes that strengthen neighborhoods and expand opportunity, building on the strong foundation established under prior leadership, including Mark Hutton, head of business banking and former Delaware regional president.

About M&T
M&T Bank Corporation is a financial holding company headquartered in Buffalo, New York. M&T's principal banking subsidiary, M&T Bank, provides banking products and services with a branch and ATM network spanning the eastern U.S. from Maine to Virginia and Washington, D.C. Trust-related services are provided in select markets in the U.S. and abroad by M&T's Wilmington Trust-affiliated companies and by M&T Bank. For more information on M&T Bank, visit www.mtb.com.

Equal Housing Lender. © 2026 M&T Bank. NMLS #381076. Member FDIC. All rights reserved.

Media Contact: 
Neil Dhillon 
(202) 768-1071 
[email protected]

SOURCE M&T Bank

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: First Solar (FSLR - Free Report) Headquartered in Tempe, AZ, First Solar, Inc. is the world’s largest thin-film PV solar module manufacturer and the largest PV solar module manufacturer in the Western Hemisphere. The company is a leading global provider of comprehensive photovoltaic (PV) solar energy solutions and specializes in designing, manufacturing, and selling solar electric power modules using a proprietary thin-film semiconductor technology. The company sells its products to project developers, system integrators and renewable energy project operators primarily in Europe and Germany in particular. First Solar also engages in designing and deploying commercial solar projects for utilities. The company also develops and sells PV solar power systems that primarily use the modules it manufactures. Additionally, it provides operations and maintenance (“O&M”) services to system owners.

FSLR is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 15.01; value investors should take notice.

Five analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.21 to $17.61 per share. FSLR also boasts an average earnings surprise of +5.4%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, FSLR should be on investors' short list.

First Solar (FSLR 5.30%) has been on an absolute roller coaster. It has more than tripled over the past five years, but that includes multiple 20% and 40% drops along the way.

Elon Musk has his eyes set on solar-powered AI data centers for SpaceX. Furthermore, the Solar Energy Industries Association released a report last year detailing how the U.S.'s AI leaders are investing billions of dollars into solar energy.

Using solar energy as an AI data center power source can put less strain on the electric grid, and First Solar fits nicely into that objective. A 2% year-to-date drop in the stock price suggests that not every investor sees this opportunity quite yet.

Image source: Getty Images.

First Solar has multi-year revenue visibility First-quarter results offered reasons for optimism, especially if First Solar continues to ride AI tailwinds. Net sales reached $1.04 billion, which was up by 24% year over year. The company cited an "increase in the volume of modules sold to third parties" as a major catalyst, which was fueled by AI demand.

Today's Change

(

-5.30

%) $

-13.94

Current Price

$

249.17

First Solar also has a contracted 47.9-gigawatt backlog, providing multiple years of high-growth revenue visibility. For instance, the company expects to sell 17.6 gigawatts at the projected 2026 midpoint and earn $5.05 billion. Megawatt rates vary by project, but the company said its 47.9 gigawatts of capacity equate to $14.4 billion in contracted backlog through 2030.

Record sales in India contributed to the results. The company sold approximately 1 gigawatt worth of energy to the country in Q1. First Solar also mentioned "substantially committed" U.S. production through 2028.

The valuation is extremely low First Solar currently has a 16.5 price-to-earnings (P/E) ratio and a 0.67 price/earnings-to-growth (PEG) ratio. Those valuations are shockingly low for a company that has achieved an annualized revenue growth rate of 25.8% over the past three years. High top-line growth has also come with rising profit margins, with net margins reaching 33% in Q1.

First Solar also has a much lower valuation than its peers. Enphase Energy trades at a 51.1 P/E ratio despite posting year-over-year revenue declines in recent quarters. Meanwhile, SolarEdge remains unprofitable, but has a projected forward P/E ratio of 208.

Demand for First Solar's utility-scale solar energy should continue to gain momentum amid the AI build-out. Not everyone will want to rely on the electric grid for power, and if Musk launches AI data centers into space, they will need solar panels. The current valuation offers a reasonable margin of safety for what can be a compelling long-term opportunity.

Marc Guberti has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends First Solar. The Motley Fool recommends Enphase Energy. The Motley Fool has a disclosure policy.

SolarEdge Technologies expands U.S. manufacturing and leveraging domestic-content products, but policy shifts and tax credit uncertainty may pressure demand.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1 or PD-L1 inhibitor therapy. Trodelvy is the first antibody-drug conjugate (ADC) to be approved in first-line metastatic TNBC in the European Union’s 27 member states, as well as Norway, Iceland and Liechtenstein.

“This approval brings a profound sense of hope to a community that has long been waiting for progress,” said Dr. Javier Cortes, Head of the International Breast Cancer Center, Madrid and Barcelona, Spain. “For women diagnosed with metastatic TNBC, particularly those who are younger, every second counts, and having an effective treatment option that can delay the progression of their disease is invaluable. This is the kind of meaningful advance our community needs.”

For many living with metastatic TNBC, the most aggressive form of breast cancer, first-line therapy may be their only line of treatment, creating an urgent need for effective treatment options to be used as early as possible.

“This approval represents a significant step forward in how we treat people with first-line metastatic TNBC in Europe,” said Mika Kakefuda Derynck, MD, Senior Vice President, Clinical Development, Oncology at Gilead Sciences. “We have long recognized the challenges that patients and clinicians face with this aggressive cancer, and we believe this approval will provide a much-needed new option for people with metastatic TNBC.”

The EC’s marketing authorization is based on data from the Phase 3 ASCENT-03 study which demonstrated a highly statistically significant and clinically meaningful progression-free survival for Trodelvy compared to standard of care chemotherapy as a first-line treatment. In ASCENT-03, Trodelvy demonstrated a 38% reduced risk of disease progression or death in patients who are not candidates for PD-1/PD-L1 inhibitors. The ASCENT-03 study utilized a patient-centered crossover design, which allowed patients in the chemotherapy arm to receive Trodelvy after their disease progressed. The EC’s approval, based on the strength of the PFS data, confirms the study's objective to demonstrate using Trodelvy earlier provides a clinical benefit over chemotherapy for metastatic TNBC patients.

Continued Global Regulatory Filings for Trodelvy in First-Line Metastatic TNBC

Gilead has submitted a supplemental filing to the European Medicines Agency for Trodelvy in combination with Keytruda® (pembrolizumab) for patients with PD-L1 positive unresectable locally advanced or metastatic TNBC, based on data from the Phase 3 ASCENT-04 study. This application is currently under review. If approved, Trodelvy has the potential to be a backbone treatment in 1L metastatic TNBC, across PD-L1 status in Europe. In the U.S., Gilead has also submitted supplemental filings to the Food and Drug Administration (FDA) for Trodelvy for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC as a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy, or in combination with Keytruda or Keytruda Qlex in patients whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.

KEYTRUDA® and KEYTRUDA QLEX™ are trademarks of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

About Triple-Negative Breast Cancer In Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitors

TNBC is the most aggressive type of breast cancer and has historically been difficult to treat, accounting for approximately 15% of all breast cancers. TNBC disproportionally impacts younger, premenopausal, and Black and Hispanic women. TNBC cells do not have estrogen and progesterone receptors and have limited HER2 expression. Due to the nature of TNBC, treatment options are extremely limited compared with other breast cancer types. TNBC has a higher chance of recurrence and metastases than other breast cancer types. The average time to metastatic recurrence for TNBC is approximately 2.6 years compared with 5 years for other breast cancers, and the relative five-year survival rate is much lower. Among women with metastatic TNBC, the five-year survival rate is 12%, compared with 28% for those with other types of mBC.

About Trodelvy

Trodelvy (sacituzumab govitecan-hziy) is a Trop-2-directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and lung cancers. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the tumor microenvironment through a bystander effect.

Outside of Europe, Gilead has submitted supplemental applications to the U.S. Food and Drug Administration (FDA) for approval of Trodelvy based on the ASCENT-03 and ASCENT-04 studies.

Healthcare professionals have substantial clinical experience with Trodelvy, with more than 75,000 breast cancer patients treated since 2020. In addition to its first-line indication approval, Trodelvy is currently approved in more than 60 countries for patients with second-line or later mTNBC and in over 50 countries for certain patients with pre-treated HR+/HER2- metastatic breast cancer. It is the only ADC with four positive Phase 3 trials in HER2-negative metastatic breast cancer and the only Trop-2-directed ADC to demonstrate a meaningful overall survival benefit in two distinct types of metastatic breast cancer.

Trodelvy is currently being evaluated in multiple ongoing Phase 3 trials across different tumor types, including in small cell lung cancer and gynecologic cancers, where previous proof-of-concept studies have demonstrated clinical activity.

U.S. Indications for Trodelvy

TRODELVY® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with:

Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. U.S. Important safety information FOR TRODELVY
BOXED WARNING: NEUTROPENIA AND DIARRHEA

TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia. Initiate anti-infective treatment in patients with febrile neutropenia without delay. TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses. CONTRAINDICATIONS

Severe hypersensitivity reaction to TRODELVY. WARNINGS AND PRECAUTIONS

Neutropenia: Severe, life-threatening, or fatal neutropenia can occur as early as the first cycle of treatment and may require dose modification. Neutropenia occurred in 64% of patients treated with TRODELVY. Grade 3-4 neutropenia occurred in 49% of patients. Febrile neutropenia occurred in 6%. Neutropenic colitis occurred in 1.4%. Primary prophylaxis with G-CSF is recommended starting in the first cycle of treatment in all patients at increased risk of febrile neutropenia, including older patients, patients with previous neutropenia, poor performance status, organ dysfunction, or multiple comorbidities. Monitor absolute neutrophil count (ANC) during treatment. Withhold TRODELVY for ANC below 1500/mm3 on Day 1 of any cycle or below 1000/mm3 on Day 8 of any cycle. Withhold TRODELVY for neutropenic fever. Treat neutropenia with G-CSF and administer prophylaxis in subsequent cycles as clinically indicated or indicated in Table 2 of USPI.

Diarrhea: Diarrhea occurred in 64% of all patients treated with TRODELVY. Grade 3-4 diarrhea occurred in 11% of patients. One patient had intestinal perforation following diarrhea. Diarrhea that led to dehydration and subsequent acute kidney injury occurred in 0.7% of all patients. Withhold TRODELVY for Grade 3-4 diarrhea and resume when resolved to ≤ Grade 1. At onset, evaluate for infectious causes and if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Additional supportive measures (e.g., fluid and electrolyte substitution) may also be employed as clinically indicated. Patients who exhibit an excessive cholinergic response to treatment can receive appropriate premedication (e.g., atropine) for subsequent treatments.

Hypersensitivity and Infusion-Related Reactions: TRODELVY can cause serious hypersensitivity reactions including life-threatening anaphylactic reactions. Severe signs and symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis, and skin reactions. Hypersensitivity reactions within 24 hours of dosing occurred in 35% of patients. Grade 3-4 hypersensitivity occurred in 2% of patients. The incidence of hypersensitivity reactions leading to permanent discontinuation of TRODELVY was 0.2%. The incidence of anaphylactic reactions was 0.2%. Pre-infusion medication is recommended. Have medications and emergency equipment to treat such reactions available for immediate use. Observe patients closely for hypersensitivity and infusion-related reactions during each infusion and for at least 30 minutes after completion of each infusion. Permanently discontinue TRODELVY for Grade 4 infusion-related reactions.

Nausea and Vomiting: TRODELVY is emetogenic and can cause severe nausea and vomiting. Nausea occurred in 64% of all patients treated with TRODELVY and Grade 3-4 nausea occurred in 3% of these patients. Vomiting occurred in 35% of patients and Grade 3-4 vomiting occurred in 2% of these patients. Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV). Withhold TRODELVY doses for Grade 3 nausea or Grade 3-4 vomiting and resume with additional supportive measures when resolved to Grade ≤ 1. Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting.

Increased Risk of Adverse Reactions in Patients with Reduced UGT1A1 Activity: Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia and may be at increased risk for other adverse reactions with TRODELVY. The incidence of Grade 3-4 neutropenia was 58% in patients homozygous for the UGT1A1*28, 49% in patients heterozygous for the UGT1A1*28 allele, and 43% in patients homozygous for the wild-type allele. The incidence of Grade 3-4 anemia was 21% in patients homozygous for the UGT1A1*28 allele, 10% in patients heterozygous for the UGT1A1*28 allele, and 9% in patients homozygous for the wild-type allele. Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue TRODELVY based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 function.

Embryo-Fetal Toxicity: Based on its mechanism of action, TRODELVY can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TRODELVY and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TRODELVY and for 3 months after the last dose.

ADVERSE REACTIONS

In the pooled safety population, the most common (≥ 25%) adverse reactions including laboratory abnormalities were decreased leukocyte count (84%), decreased neutrophil count (75%), decreased hemoglobin (69%), diarrhea (64%), nausea (64%), decreased lymphocyte count (63%), fatigue (51%), alopecia (45%), constipation (37%), increased glucose (37%), decreased albumin (35%), vomiting (35%), decreased appetite (30%), decreased creatinine clearance (28%), increased alkaline phosphatase (28%), decreased magnesium (27%), decreased potassium (26%), and decreased sodium (26%).

In the ASCENT study (locally advanced or metastatic triple-negative breast cancer), the most common adverse reactions (incidence ≥25%) were fatigue, diarrhea, nausea, alopecia, constipation, vomiting, abdominal pain, and decreased appetite. The most frequent serious adverse reactions (SAR) (>1%) were neutropenia (7%), diarrhea (4%), and pneumonia (3%). SAR were reported in 27% of patients, and 5% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the ASCENT study were reduced neutrophils, leukocytes, and lymphocytes.

In the TROPiCS-02 study (locally advanced or metastatic HR-positive, HER2-negative breast cancer), the most common adverse reactions (incidence ≥25%) were diarrhea, fatigue, nausea, alopecia, and constipation. The most frequent serious adverse reactions (SAR) (>1%) were diarrhea (5%), febrile neutropenia (4%), neutropenia (3%), abdominal pain, colitis, neutropenic colitis, pneumonia, and vomiting (each 2%). SAR were reported in 28% of patients, and 6% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the TROPiCS-02 study were reduced neutrophils and leukocytes.

DRUG INTERACTIONS

UGT1A1 Inhibitors: Concomitant administration of TRODELVY with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38. Avoid administering UGT1A1 inhibitors with TRODELVY.

UGT1A1 Inducers: Exposure to SN-38 may be reduced in patients concomitantly receiving UGT1A1 enzyme inducers. Avoid administering UGT1A1 inducers with TRODELVY.

Please see full Prescribing Information, including BOXED WARNING.

About Gilead and Kite Oncology

Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing and additional clinical trials or studies, including those involving Trodelvy; uncertainties relating to regulatory applications and related filing and approval timelines, including such as the pending applications for Trodelvy in 1L mTNBC and potential applications for programs and/or indications currently under evaluation, and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the possibility that Gilead may make a strategic decision to discontinue development of these programs and, as a result, these programs may never be successfully commercialized for the indications currently under evaluation; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

Trodelvy, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

U.S. Prescribing Information for Trodelvy, including BOXED WARNING, is available at www.gilead.com.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

More News From Gilead Sciences, Inc.

In the latest close session, Enbridge (ENB - Free Report) was down 2.17% at $54.47. The stock's performance was behind the S&P 500's daily loss of 1.22%. Meanwhile, the Dow lost 0.98%, and the Nasdaq, a tech-heavy index, lost 1.35%.

Shares of the oil and natural gas transportation and power transmission company witnessed a loss of 1.95% over the previous month, beating the performance of the Oils-Energy sector with its loss of 6.85%, and underperforming the S&P 500's gain of 1.56%.

Analysts and investors alike will be keeping a close eye on the performance of Enbridge in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.44, marking a 6.38% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $11.22 billion, reflecting a 4.41% rise from the equivalent quarter last year.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.18 per share and a revenue of $51.3 billion, representing changes of +0.93% and +10.11%, respectively, from the prior year.

It's also important for investors to be aware of any recent modifications to analyst estimates for Enbridge. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.17% upward. At present, Enbridge boasts a Zacks Rank of #3 (Hold).

Digging into valuation, Enbridge currently has a Forward P/E ratio of 25.57. This valuation marks a premium compared to its industry average Forward P/E of 18.56.

The Oil and Gas - Production and Pipelines industry is part of the Oils-Energy sector. This industry, currently bearing a Zacks Industry Rank of 62, finds itself in the top 26% echelons of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Growth stocks continue leading the market higher. If you're an income investor shopping around for a new dividend-paying company, however, you might be a bit discouraged. That's because the market's relentless bullishness, which has driven the S&P 500 (^GSPC 1.44%) more than 100% higher since late 2022 (and up 16% just since late March), has also pared the index's dividend yield down to a record low of just over 1%. It suggests there are no great yields to be found anywhere.

Now dig deeper. They're out there, if you're willing to look a bit off the beaten path. A company called Enbridge (ENB +1.67%) fits the bill, with its forward-looking dividend yield of 5.1%.

Enbridge is oil-price-agnostic It's not a household name. There's a good chance, however, that your household regularly depends on the service it provides.

Enbridge owns over 18,000 miles' worth of natural gas and crude oil pipelines in the United States and Canada, moving 5.8 million barrels of oil and liquids every day. The company handles 30% of the crude drilled in North America, in fact, and 20% of the gas that the United States consumes.

Today's Change

(

1.67

%) $

0.92

Current Price

$

55.72

Yes, the energy business that's known for its increasingly volatile prices. Oil prices soared because of the military conflict with Iran, for instance, but are now plummeting on the International Energy Agency's call for a supply glut next year.

Here's the thing: Enbridge's business isn't built around the price of oil. It's essentially a tollbooth, charging other energy companies a fee based on the amount of natural gas and crude oil it's pushing through its pipelines. As long as North America continues consuming both, Enbridge's reliable revenue stream remains intact. This, of course, is ideal for supporting recurring dividend payments.

Image source: Getty Images.

And this demand is holding up. The United States Energy Information Administration reports the nation consumed nearly 2.78 trillion cubic feet of natural gas in March, up 1% year over year. As for crude oil, the EIA says the industry delivered 2% more of it in March of this year than it did in March of last year. This growth trend hasn't changed in the meantime, either, despite higher prices. Indeed, the U.S. Energy Information Administration predicts domestic demand for natural gas will reach record levels this year.

Now all of a sudden Enbridge's 31-year streak of annual dividend increases makes sense.

Perfect for its purpose Sure, there will come a time when the world weans itself from gas and oil in favor of more environmentally friendly renewables. That time isn't anywhere on the horizon, however. The International Energy Agency now doesn't expect the world to reach "peak oil" -- the point at which demand for crude oil stops growing and begins permanently shrinking -- until 2050, and even then we'll still need plenty of gas and oil past that point. There's good money to be made in the business in the meantime.

Even so, Enbridge is preparing for its inevitable distant future by investing in renewables like wind farms and solar power production facilities. The upside of this strategic shift is that it's got plenty of time to do it right.

The one arguable downside? There's not a lot of capital appreciation to be reaped here. Enbridge is first and foremost an income growth holding, albeit a good one.

The global economy is always adapting and evolving. As a result, companies need to remain innovative to stay ahead. Some companies have done an excellent job at keeping up with the times over the years, enabling them to grow their earnings and dividends for decades.

Enbridge (ENB +1.67%), ExxonMobil (XOM +0.91%), and NextEra Energy (NEE +0.41%) stand out for their dividend growth records. These energy companies have increased their payouts each year for more than three decades, which should continue for at least the next 10 years despite the sector's shift toward cleaner energy. That makes them ideal dividend stocks to buy and hold for the next decade.

Image source: Getty Images.

Steadily growing cleaner A decade ago, Enbridge got nearly three-quarters of its earnings from its oil and liquids pipeline segment, with the rest from lower-carbon energy (gas and renewable power). Today, more than half its earnings come from lower-carbon energy. Enbridge has invested heavily to grow its cleaner energy platforms through acquisitions and organic expansion projects.

The Canadian pipeline and utility company's shift to lower-carbon energy should continue in the coming decade. Enbridge ended the first quarter with 40 billion Canadian dollars ($28 billion) of secured growth capital projects in the backlog, which should enter service by the early 2030s. While its projects span liquids, gas, and renewables, the bulk of its spending is on cleaner energy. Meanwhile, it's pursuing about CA$50 billion ($35 billion) in additional growth capital projects, which it could approve by 2030, primarily in gas and renewables.

Today's Change

(

1.67

%) $

0.92

Current Price

$

55.72

These projects should support about 5% annual cash flow per share growth after this year. That will give Enbridge the fuel to continue increasing its more than 5%-yielding dividend in the coming decade. The company has now raised its payout for 31 consecutive years (in Canadian dollars).

Investing in the energy needed today and in the future ExxonMobil's current focus is on becoming an even more profitable oil and gas producer. It's investing heavily to develop its advantaged resources (lowest cost and highest margins) while also executing a multi-year structural cost-savings program. This strategy should grow its earnings capacity by $25 billion and cash flow by $35 billion by 2030, at the same margins and prices as in 2024. That's double-digit annual growth rates.

Today's Change

(

0.91

%) $

1.26

Current Price

$

139.73

The oil giant's plan would enable it to produce $145 billion in surplus cash during that period at $65 oil. That would give Exxon the funds to continue increasing its 3%-yielding dividend, which it has done for 43 consecutive years.

While Exxon's main focus is on producing oil and gas, the energy giant is also ramping up its investments in the energy sources we'll need in the future. It's developing carbon capture and storage, lithium, and biofuels projects. Additionally, Exxon is investing in new businesses, including Proxxima (polyolefin thermoset resin systems that outperform epoxy and polyurethane) and carbon materials. These businesses have the potential to reach $13 billion in earnings by 2040, while driving Exxon's growth for decades.

Accelerating the strategy NextEra Energy owns the country's largest electric utility and is a leading clean energy development company. It has invested heavily in renewable energy over the years, driving robust growth. NextEra has increased its nearly 3%-yielding dividend for more than 30 consecutive years, including delivering double-digit compound annual dividend growth over the last two decades.

Today's Change

(

0.41

%) $

0.35

Current Price

$

86.43

The company currently expects to invest between $295 billion and $325 billion in capex through 2032 to support surging U.S. power demand. That should give NextEra Energy the power to grow its adjusted earnings per share at a compound annual rate of more than 8% through 2032, with it highly likely to continue growing at that rate through at least 2035. That should support continued dividend increases, with NextEra targeting 6% compound annual growth in 2027 and 2028.

NextEra Energy recently pounced on the opportunity to accelerate its growth by agreeing to acquire Dominion Energy. The deal will create the world's largest regulated electric utility business and boost its growth rate to more than 9% annually through 2032, a rate it believes it can extend through 2035. The larger-scale company will be able to operate more efficiently, putting it in an even stronger position to capitalize on the AI power boom. As a result, it should have plenty of power to continue increasing its dividend in the decade ahead.

These dividends should continue rising in the coming decade Exxon, Enbridge, and NextEra Energy have already increased their dividends every year for decades. That upward trend should continue over the coming decade as they support the world's growing energy needs. Their combinations of higher yields and visible growth make them ideal dividend stocks to buy and hold for the next 10 years.